Literature DB >> 12478119

Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.

Joseph C Presti1, Gerard J O'Dowd, M Craig Miller, Rubina Mattu, Robert W Veltri.   

Abstract

PURPOSE: We assessed the impact of age and prostate specific antigen (PSA) on extended systematic biopsy schemes for detecting prostate carcinoma and better characterized these tumors as a function of patient age and PSA.
MATERIALS AND METHODS: We retrospectively reviewed the records of 2,299 consecutive patients who underwent initial systematic biopsy performed by 167 community based urologists. A total of 12 systematic biopsies of the peripheral zone were obtained in all patients. Various biopsy schemes were then created and cancer detection rates were calculated. Data analyses were stratified by patient age and PSA.
RESULTS: On biopsy 1,020 patients (44.4%) had cancer. Detection rates increased with increasing patient age. Increasing age and PSA were associated with larger, higher grade tumors. Overall and unique site specific cancer detection rates were highest for laterally directed biopsies and the apical biopsy of the standard sextant scheme. The 12 site biopsy scheme outperformed all other schemes in patients with PSA 7 ng./ml. or less and in those 60 years or younger. The variation in age related and PSA related detection rates was greatest for the standard sextant scheme and this variability decreased for extended biopsy schemes.
CONCLUSIONS: This multi-practice community based study confirms the inadequacy of sextant biopsies and emphasizes the need for extended peripheral zone sampling of the lateral aspect of the prostate. Generally increasing patient age and PSA were associated with larger, higher grade tumors. Extended biopsy schemes minimize PSA and age related detection rates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12478119     DOI: 10.1097/01.ju.0000036482.46710.7e

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  86 in total

1.  [Complications of transrectal prostate biopsy. Determination of current status].

Authors:  H W Gottfried; B Volkmer
Journal:  Urologe A       Date:  2003-08       Impact factor: 0.639

Review 2.  The technique of ultrasound guided prostate biopsy.

Authors:  Imre Romics
Journal:  World J Urol       Date:  2004-09-29       Impact factor: 4.226

3.  An automated neural-fuzzy approach to malignant tumor localization in 2D ultrasonic images of the prostate.

Authors:  Samar Samir Mohamed; J M Li; M M A Salama; G H Freeman; H R Tizhoosh; A Fenster; K Rizkalla
Journal:  J Digit Imaging       Date:  2011-06       Impact factor: 4.056

Review 4.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

5.  Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary?

Authors:  Arnold I Chin; Dhiren S Dave; Jacob Rajfer
Journal:  Rev Urol       Date:  2007

6.  Prostate biopsy: current status and limitations.

Authors:  Joseph C Presti
Journal:  Rev Urol       Date:  2007

7.  Using biopsy to detect prostate cancer.

Authors:  Shahrokh F Shariat; Claus G Roehrborn
Journal:  Rev Urol       Date:  2008

8.  Incremental value of transition zone and midline apical biopsy at baseline TRUS-guided biopsy for prostate cancer detection.

Authors:  D M Somford; W Vreuls; T S Jansen; J P van Basten; H Vergunst
Journal:  World J Urol       Date:  2013-07-20       Impact factor: 4.226

9.  Pathologic findings in patients with targeted magnetic resonance imaging-guided prostate needle core biopsies.

Authors:  Rachel L Geller; Sherif G Nour; Adeboye O Osunkoya
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.

Authors:  Geoffrey A Sonn; Edward Chang; Shyam Natarajan; Daniel J Margolis; Malu Macairan; Patricia Lieu; Jiaoti Huang; Frederick J Dorey; Robert E Reiter; Leonard S Marks
Journal:  Eur Urol       Date:  2013-03-17       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.